TITLE:
Cytomegalovirus Seroprevalence among Parturient Women at Panzi General Referral Hospital, Bukavu, Democratic Republic of the Congo
AUTHORS:
Julien Bwama, Andrea Mbozi, Justin Mongwa Mbikilile, Augustin Bwira, Parvine Bisimwa, Patron Bisimwa, Olivier Nyakio
KEYWORDS:
Cytomegalovirus, Seroprevalence, Parturient Women, IgM, IgG, Bukavu, DR Congo
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.16 No.11,
November
16,
2026
ABSTRACT: Introduction: Cytomegalovirus (CMV) is a ubiquitous herpesvirus that establishes lifelong latent infection, and its global seroprevalence among women of reproductive age is close to 86%. Yet very little is known about CMV seroprevalence among parturient women in the Democratic Republic of the Congo. Objective: To estimate the seroprevalence of anti-CMV antibodies (IgM and IgG) and to identify associated factors among parturient women at Panzi General Referral Hospital in Bukavu. Methods: We conducted a cross-sectional descriptive study with an analytical component, using convenience sampling, from 1 October 2024 to 30 September 2025. A total of 551 consecutive parturient women with conclusive IgG and IgM results were included in the analysis. Anti-CMV IgM and IgG antibodies were detected using a standardized ELISA. Bivariate analysis followed by multivariable logistic regression was performed in SPSS version 26 to identify associated factors, with statistical significance set at p Results: Seroprevalence was 63.5% for IgG and 36.8% for IgM. Educational level was significantly associated with both IgM and IgG positivity (p = 0.001), and employment status with IgG positivity (p = 0.005). Parity was associated with IgM (p = 0.015) and IgG (p = 0.018) seropositivity, and multivariable logistic regression confirmed that parity (p = 0.018) and educational level (p Conclusion: CMV seroprevalence is high among parturient women in Bukavu; however, IgM positivity alone does not establish recent infection, and the IgM estimate requires confirmation with IgG avidity or molecular testing. These findings highlight the need for stronger prevention strategies, including awareness-raising among pregnant women. Integrating CMV screening into routine antenatal care could be considered, but would first require evidence on confirmatory testing pathways and on clinical benefit.